Comparison · NCT04452318-49e71c4a
R10933 + R10987 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. R10933 + R10987 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933. Trial comparisons, record NCT04452318-49e71c4a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04452318-49e71c4a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.827 | 0.808 | 0.845 | wilson | |
| Risk in group 2 | 0.961 | 0.951 | 0.97 | wilson | |
| Risk difference, group 1 minus group 2 | -0.134 | -0.156 | -0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.86 | 0.839 | 0.881 | log | |
| Odds ratio, group 1 over group 2 | 0.192 | 0.144 | 0.255 | log | |
| Number needed to treat, for one fewer participant with the outcome on R10933 + R10987 than on Placebo | 7.44 | 6.43 | 8.79 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | R10933 + R10987 | Participants received a single 1200mg intravenous dose of REGN10933+REGN10987 | 1,319 | 1,595 | OG001 |
| Group 2 | Placebo | Overall Adult and Adolescent Subjects (≥12years) Who Are SARS-CoV-2 RT-qPCR negative at baseline | 1,544 | 1,606 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933
- Description
- Time frame
- Up to 8 months
- Population
This ADA analysis set (AAS) includes all treated subjects who received study drug and had at least 1 non-missing ADA result after study drug administration. The AAS is based on the actual treatment received.
Source ClinicalTrials.gov
Trial
- Title
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
- NCT number
- NCT04452318
- Phases
- PHASE3
- Conditions
- Healthy Participants
- Interventions
- REGN10933 + REGN10987, Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2023-05-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04452318?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04452318-49e71c4a